P-007: Exploring a safety switch in NKG2D and BCMA CAR NK-92MI immunotherapy

Martín, Elena Maroto; Encinas, Jessica; García-Ortiz, Almudena; Castellano, Esther; Ugalde, Laura; Alonso, Rafael; Leivas, Alejandra; Paciello, Mari Liz; Garrido, Vanesa; Martín-Antonio, Beatriz; Suñé, Guillermo; Cedena, Teresa; Powell, Daniel J.; Rı́o, Paula; Martínez‐López, Joaquín; Valeri, Antonio

doi:10.1016/s2152-2650(21)02141-8

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a TM glycoprotein highly expressed in myeloma cells, B cell maturation antigen (BCMA) is the leading target for CAR NK therapy for multiple myeloma (MM) 174 . BCMA CAR NK cells coexpressing cytokine receptor CXCR4, which facilitates trafficking of NK cells to BM via binding to CXCR12 expressed by BM cells, exhibited improved migration and BM homing capacity 175 …”

Section: Potential Targets For Car Nk Therapymentioning

confidence: 99%

See 1 more Smart Citation

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy

Wang,

Jin,

Zhuang

et al. 2023

MedComm

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell therapy for malignancies. However, some obstacles, including side effects such as graft‐versus‐host disease and cytokine release syndrome, therapy resistance, limited sources, as well as high cost, limited the application of CAR T cells. Recently, CAR natural killer (NK) cells have been pursued as the effector cells for adoptive immunotherapy for their attractive merits of strong intrinsic antitumor activity and relatively mild side effects. Additionally, CAR NK cells can be available from various sources and do not require strict human leukocyte antigen matching, which suggests them as promising “off‐the‐shelf” products for clinical application. Although the use of CAR NK cells is restrained by the limited proliferation and impaired efficiency within the immunosuppressive tumor microenvironment, further investigation in optimizing CAR structure and combination therapies will overcome these challenges. This review will summarize the advancement of CAR NK cells, CAR NK cell manufacture, the clinical outcomes of CAR NK therapy, the challenges in the field, and prospective solutions. Besides, we will discuss the emerging application of other immune cells for CAR engineering. Collectively, this comprehensive review will provide a valuable and informative summary of current progress and evaluate challenges and future opportunities of CAR NK cells in tumor treatment.

show abstract

Section: Potential Targets For Car Nk Therapymentioning

confidence: 99%

“…174 BCMA CAR NK cells coexpressing cytokine receptor CXCR4, which facilitates trafficking of NK cells to BM via binding to CXCR12 expressed by BM cells, exhibited improved migration and BM homing capacity. 175…”

Section: Potential Targets For Car Nk Therapymentioning

confidence: 99%

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy

Wang,

Jin,

Zhuang

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…Moreover, Kang et al designed a universal modifiable cotinine-specific CAR which is bound to a cotinine conjugator to target multiple cancer antigens (27). Furthermore, the inducible caspase9 (iCasp9) suicide gene is used in on/off logic-gated CAR to switch off the killing mechanism of CAR-NK cells when needed (28).…”

Section: Introductionmentioning

confidence: 99%

Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges

Kong,

Sa’ad,

Vijayan

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is a novel immunotherapy targeting cancer cells via the generation of chimeric antigen receptors on NK cells which recognize specific cancer antigens. CAR-NK cell therapy is gaining attention nowadays owing to the ability of CAR-NK cells to release potent cytotoxicity against cancer cells without side effects such as cytokine release syndrome (CRS), neurotoxicity and graft-versus-host disease (GvHD). CAR-NK cells do not require antigen priming, thus enabling them to be used as “off-the-shelf” therapy. Nonetheless, CAR-NK cell therapy still possesses several challenges in eliminating cancer cells which reside in hypoxic and immunosuppressive tumor microenvironment. Therefore, this review is envisioned to explore the current advancements and limitations of CAR-NK cell therapy as well as discuss strategies to overcome the challenges faced by CAR-NK cell therapy. This review also aims to dissect the current status of clinical trials on CAR-NK cells and future recommendations for improving the effectiveness and safety of CAR-NK cell therapy.

show abstract

P-007: Exploring a safety switch in NKG2D and BCMA CAR NK-92MI immunotherapy

Cited by 2 publications

References 0 publications

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy

Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges

Contact Info

Product

Resources

About